000288522 001__ 288522
000288522 005__ 20250824022513.0
000288522 0247_ $$2doi$$a10.1016/j.canep.2024.102545
000288522 0247_ $$2pmid$$apmid:38377945
000288522 0247_ $$2ISSN$$a1877-7821
000288522 0247_ $$2ISSN$$a1877-783X
000288522 0247_ $$2altmetric$$aaltmetric:160032298
000288522 037__ $$aDKFZ-2024-00392
000288522 041__ $$aEnglish
000288522 082__ $$a610
000288522 1001_ $$aVon Holle, Ann$$b0
000288522 245__ $$aBMI and breast cancer risk around age at menopause.
000288522 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000288522 3367_ $$2DRIVER$$aarticle
000288522 3367_ $$2DataCite$$aOutput Types/Journal article
000288522 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708604134_8524
000288522 3367_ $$2BibTeX$$aARTICLE
000288522 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288522 3367_ $$00$$2EndNote$$aJournal Article
000288522 520__ $$aA high body mass index (BMI, kg/m2) is associated with decreased risk of breast cancer before menopause, but increased risk after menopause. Exactly when this reversal occurs in relation to menopause is unclear. Locating that change point could provide insight into the role of adiposity in breast cancer etiology.We examined the association between BMI and breast cancer risk in the Premenopausal Breast Cancer Collaborative Group, from age 45 up to breast cancer diagnosis, loss to follow-up, death, or age 55, whichever came first. Analyses included 609,880 women in 16 prospective studies, including 9956 who developed breast cancer before age 55. We fitted three BMI hazard ratio (HR) models over age-time: constant, linear, or nonlinear (via splines), applying piecewise exponential additive mixed models, with age as the primary time scale. We divided person-time into four strata: premenopause; postmenopause due to natural menopause; postmenopause because of interventional loss of ovarian function (bilateral oophorectomy (BO) or chemotherapy); postmenopause due to hysterectomy without BO. Sensitivity analyses included stratifying by BMI in young adulthood, or excluding women using menopausal hormone therapy.The constant BMI HR model provided the best fit for all four menopausal status groups. Under this model, the estimated association between a five-unit increment in BMI and breast cancer risk was HR=0.87 (95% CI: 0.85, 0.89) before menopause, HR=1.00 (95% CI: 0.96, 1.04) after natural menopause, HR=0.99 (95% CI: 0.93, 1.05) after interventional loss of ovarian function, and HR=0.88 (95% CI: 0.76, 1.02) after hysterectomy without BO.The BMI breast cancer HRs remained less than or near one during the 45-55 year age range indicating that the transition to a positive association between BMI and risk occurs after age 55.
000288522 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000288522 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288522 650_7 $$2Other$$aBody mass index
000288522 650_7 $$2Other$$aBreast neoplasms
000288522 650_7 $$2Other$$aMiddle aged
000288522 650_7 $$2Other$$aPostmenopause
000288522 650_7 $$2Other$$aPremenopause
000288522 7001_ $$aAdami, Hans-Olov$$b1
000288522 7001_ $$aBaglietto, Laura$$b2
000288522 7001_ $$aBerrington, Amy$$b3
000288522 7001_ $$aBertrand, Kimberly A$$b4
000288522 7001_ $$aBlot, William$$b5
000288522 7001_ $$aChen, Yu$$b6
000288522 7001_ $$aDeHart, Jessica Clague$$b7
000288522 7001_ $$aDossus, Laure$$b8
000288522 7001_ $$aEliassen, A Heather$$b9
000288522 7001_ $$aFournier, Agnes$$b10
000288522 7001_ $$aGarcia-Closas, Montse$$b11
000288522 7001_ $$aGiles, Graham$$b12
000288522 7001_ $$aGuevara, Marcela$$b13
000288522 7001_ $$aHankinson, Susan E$$b14
000288522 7001_ $$aHeath, Alicia$$b15
000288522 7001_ $$aJones, Michael E$$b16
000288522 7001_ $$aJoshu, Corinne E$$b17
000288522 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b18$$udkfz
000288522 7001_ $$aKirsh, Victoria A$$b19
000288522 7001_ $$aKitahara, Cari M$$b20
000288522 7001_ $$aKoh, Woon-Puay$$b21
000288522 7001_ $$aLinet, Martha S$$b22
000288522 7001_ $$aPark, Hannah Lui$$b23
000288522 7001_ $$aMasala, Giovanna$$b24
000288522 7001_ $$aMellemkjaer, Lene$$b25
000288522 7001_ $$aMilne, Roger L$$b26
000288522 7001_ $$aO'Brien, Katie M$$b27
000288522 7001_ $$aPalmer, Julie R$$b28
000288522 7001_ $$aRiboli, Elio$$b29
000288522 7001_ $$aRohan, Thomas E$$b30
000288522 7001_ $$aShrubsole, Martha J$$b31
000288522 7001_ $$aSund, Malin$$b32
000288522 7001_ $$aTamimi, Rulla$$b33
000288522 7001_ $$aTin Tin, Sandar$$b34
000288522 7001_ $$aVisvanathan, Kala$$b35
000288522 7001_ $$aVermeulen, Roel Ch$$b36
000288522 7001_ $$aWeiderpass, Elisabete$$b37
000288522 7001_ $$aWillett, Walter C$$b38
000288522 7001_ $$aYuan, Jian-Min$$b39
000288522 7001_ $$aZeleniuch-Jacquotte, Anne$$b40
000288522 7001_ $$aNichols, Hazel B$$b41
000288522 7001_ $$aSandler, Dale P$$b42
000288522 7001_ $$aSwerdlow, Anthony J$$b43
000288522 7001_ $$aSchoemaker, Minouk J$$b44
000288522 7001_ $$aWeinberg, Clarice R$$b45
000288522 773__ $$0PERI:(DE-600)2498032-8$$a10.1016/j.canep.2024.102545$$gVol. 89, p. 102545 -$$p102545$$tCancer epidemiology$$v89$$x1877-7821$$y2024
000288522 8564_ $$uhttps://inrepo02.dkfz.de/record/288522/files/1-s2.0-S1877782124000249-main.pdf
000288522 8564_ $$uhttps://inrepo02.dkfz.de/record/288522/files/1-s2.0-S1877782124000249-main.pdf?subformat=pdfa$$xpdfa
000288522 909CO $$ooai:inrepo02.dkfz.de:288522$$pVDB
000288522 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000288522 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000288522 9141_ $$y2024
000288522 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEMIOL : 2022$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000288522 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000288522 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000288522 980__ $$ajournal
000288522 980__ $$aVDB
000288522 980__ $$aI:(DE-He78)C020-20160331
000288522 980__ $$aUNRESTRICTED